Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects

Cinfa

Status and phase: Completed; Phase 1

Conditions: Clinical Pharmacology

Treatments: Biological: B12019 and Neulasta

Study type: Interventional

Funder types: Industry

Identifiers

NCT02629562

B12019-101

Details and patient eligibility

About

Multi-centre, double-blind, randomised, 2-way cross-over study to investigate the PK and PD of B12019 as compared to Neulasta® administered as a single subcutaneous (s.c.) dose in healthy male subjects. B12019 or Neulasta will be administered by s.c. injection.

Enrollment: 172 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male subjects
• Age ≥18 and ≤55 years
• BMI 22.0 - 28.0 kg/m2
• Non-smokers for at least 6 months prior to study start
• General good health, based on a comprehensive medical history and physical examination
• Adequate organ function and normal laboratory values (unless the investigator considers an abnormality to be clinically not relevant)
• Negative hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) tests at screening
• Signed informed consent

Exclusion criteria

• Known hypersensitivity to Escherichia coli derived proteins, pegfilgrastim, filgrastim or any other component of B12019 or Neulasta®
• Previous exposure to filgrastim or pegfilgrastim
• History of drug or alcohol abuse
• Blood donations in the past 3 months prior to study start, or bone marrow or stem cell donor in the past 12 months (first dose)
• Medical history of haematological disease, including sickle cell disorders
• Recent infection (within 1 week prior to first dose)
• Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, inflammatory or neurological diseases, that in the opinion of the investigator may interfere with the aim of the study
• Participation in an interventional or Phase I study in the last 3 months or is current a follow-up visit schedule for any study, or has participation in more than three studies of experimental drug products in the past 12 months prior to screening
• Subjects with ANC values outside the normal laboratory range at screening
• Use of prescription or over-the-counter drugs including vitamins within 4 weeks of first dosing
• Abnormalities in ECG
• Signs of dermatitis or skin abnormalities affecting the administration area and surroundings
• History of cancer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

172 participants in 2 patient groups

Arm 1

Experimental group

Description:

first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously

Treatment:

Biological: B12019 and Neulasta

Arm 2

Experimental group

Description:

first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously

Treatment:

Biological: B12019 and Neulasta